JPMorgan downgraded insulin pump maker Insulet to Neutral from Overweight and slashed its price target to $152 from $275, citing slowing U.S. sales growth, rising attrition among Type 2 diabetes patients, and a weaker-than-expected outlook for 2027. The brokerage removed the stock from its Analyst Focus List, arguing that decelerating new patient additions, higher Type 2 patient attrition, and looming competition in the patch pump market could weigh on growth. JPMorgan lowered its 2027 revenue forecast by 7.6% to $3.67 billion and cut its adjusted EPS estimate by 8.8% to $7.62, while making only modest changes to its 2026 forecasts. The firm said management's early commentary for 2027 appeared too optimistic and expects investors to remain cautious until growth stabilizes and earnings expectations are reset. International performance remained solid, supported by strong Omnipod adoption and expansion into markets such as Spain and Australia, but JPMorgan believes those positives are likely to be overshadowed by slowing U.S. growth and intensifying competition expected to emerge in 2027.
Insulet CorporationJPMorgan downgrades Insulet to Neutral and cuts price target to $152, citing slowing U.S. growth and competition.
JPMorgan Chase & Co